Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $117.00.

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada cut their price objective on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Leerink Partners decreased their target price on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Stifel Nicolaus increased their price target on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, HC Wainwright raised their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 2,631 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the sale, the chief operating officer owned 20,655 shares in the company, valued at $2,133,661.50. This represents a 11.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jolanda Howe sold 968 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40. Following the transaction, the senior vice president owned 4,503 shares of the company’s stock, valued at $465,159.90. This represents a 17.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Emerald Advisers LLC lifted its holdings in Mirum Pharmaceuticals by 20.9% in the third quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock valued at $27,095,000 after acquiring an additional 63,834 shares during the period. Candriam S.C.A. grew its stake in shares of Mirum Pharmaceuticals by 8.0% during the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock worth $29,546,000 after purchasing an additional 30,021 shares during the period. TimesSquare Capital Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $22,041,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Mirum Pharmaceuticals during the 3rd quarter valued at approximately $808,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $503,000.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $92.64 on Tuesday. The firm has a market capitalization of $5.59 billion, a PE ratio of -193.00 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $109.28. The company’s fifty day moving average price is $95.73 and its 200-day moving average price is $80.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter last year, the business earned $1.00 EPS. The business’s revenue was up 49.8% on a year-over-year basis. On average, equities research analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.